Ipamorelin vs Tesamorelin
Both compounds drive growth-hormone release through different receptor targets. Ipamorelin is a selective ghrelin-receptor agonist developed in late-1990s pharmacology. Tesamorelin is a stabilised GHRH analogue with an FDA-approved indication in HIV-associated lipodystrophy. This page summarises how the published research separates them.
Side-by-side comparison
| Property | Compound A | Compound B |
|---|---|---|
| Receptor target | Selective ghrelin receptor (GHS-R1a) agonist | GHRH receptor (stabilised GHRH analogue with N-terminal trans-3-hexenoic acid modification) |
| Structural class | Synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) | Stabilised 44-residue GHRH analogue with protease-resistant N-terminus |
| Approximate molecular weight | 711.9 g/mol | ~5136 g/mol |
| Selectivity profile | Minimal cortisol, prolactin, ACTH, aldosterone release across the tested dose range | GHRH-receptor selective; activates the endogenous GHRH signalling axis on pituitary somatotrophs |
| Regulatory status | Research compound; not approved by the FDA or Health Canada as a human therapeutic | FDA-approved for HIV-associated lipodystrophy under a separate brand name; research-grade vials sold for laboratory use |
| Clinical dosing (published) | Microgram-per-kilogram range in human pharmacology pilots | 2 mg subcutaneously once daily (FDA-approved dose) |
| Reconstitution | Bacteriostatic water; lyophilised vial format | Bacteriostatic water; lyophilised vial format |
| Ronin catalog vial size | 10 mg lyophilised | 10 mg lyophilised |
How they differ in mechanism
Ipamorelin engages the ghrelin receptor (GHS-R1a) on the pituitary and hypothalamus. The selectivity profile is the defining feature: GH release occurs with minimal concurrent release of cortisol, prolactin, ACTH, and aldosterone. This clean secretagogue profile distinguished it from earlier-generation GH-releasing peptides (GHRP-2, GHRP-6, hexarelin) that drove non-trivial off-target hormone elevations alongside the GH response.
Tesamorelin engages the GHRH receptor on pituitary somatotrophs as a stabilised analogue of the native GHRH(1-44) peptide. The N-terminal trans-3-hexenoic acid modification provides protease resistance and extended plasma persistence relative to native GHRH. The body-composition effects characterised in the HIV-associated lipodystrophy registration trials trace back to sustained GH-axis activation and downstream visceral-adipose-tissue reduction.
The practical consequence in research is that the two compounds engage non-overlapping receptor pathways (ghrelin receptor versus GHRH receptor) and can be stacked in protocol design for synergistic GH-pulse amplitude, or compared head-to-head for receptor-pathway-attribution studies. The receptor-selectivity distinction maps directly onto their different pharmacology literatures.
How research has examined each
The ipamorelin literature concentrates on selective GH-secretagogue pharmacology, GH-pulse characterisation, bone-mineral-content endpoints, and postoperative-ileus applications. The published work spans rodent pharmacology, pig and dog pharmacokinetics, and a small number of human pilot reports.
The tesamorelin literature concentrates on HIV-associated lipodystrophy, visceral-adipose-tissue reduction, and NAFLD endpoints. The published work includes the FDA registration trials (Falutz 2007, 2008), long-term safety data, and investigator-initiated extensions into non-alcoholic fatty liver disease in HIV (Stanley 2019). The depth of clinical evidence in the lipodystrophy population is the strongest distinguishing feature of the tesamorelin literature.
The two literatures rarely cite one another directly. Investigators interested in GH-axis pharmacology read both, but the primary endpoint domains (selective-secretagogue-profile characterisation for ipamorelin, body-composition in lipodystrophy for tesamorelin) are non-overlapping. Where the two appear together in reviews, both are positioned alongside other GH-axis compounds (CJC-1295, sermorelin, GHRP-2) as a class.
Stacking considerations in research contexts
The receptor complementarity (ghrelin receptor on one side, GHRH receptor on the other) provides a mechanistic basis for co-administration in research protocols seeking maximal GH-pulse amplitude. However, ipamorelin is more commonly stacked with CJC-1295 No DAC (the modified GHRH(1-29) variant) than with tesamorelin in research-community convention, because the CJC-1295 No DAC variant preserves the pulsatile release pattern that more closely resembles endogenous GHRH-driven release. Both are sold as separate lyophilised vials in the Ronin catalog for investigators sourcing per-compound vials.
Sourcing both at Ronin
Both compounds ship as 10 mg lyophilised peptide in glass vials with certificate-of-analysis documentation. The ipamorelin vial page and the tesamorelin vial page carry per-compound spec sheets. Both are sold strictly as research-grade reagents for laboratory and bench-research applications.
Frequently asked research questions
Do they engage the same receptor?
No. Ipamorelin engages the ghrelin receptor (GHS-R1a). Tesamorelin engages the GHRH receptor. The two pathways are non-overlapping.
Is tesamorelin approved for clinical use?
Yes, tesamorelin is FDA-approved for HIV-associated lipodystrophy under a separate brand name. Ipamorelin is not approved by the FDA or Health Canada as a human therapeutic.
Why is ipamorelin more commonly stacked with CJC-1295 No DAC than with tesamorelin?
CJC-1295 No DAC (modified GHRH(1-29)) preserves the pulsatile release pattern that more closely resembles endogenous GHRH-driven release, while tesamorelin (stabilised GHRH(1-44) analogue) has a longer functional duration per dose. The pulsatile profile is the usual protocol-design preference for stacking with ipamorelin.
Do they share reconstitution practice?
Yes. Both are lyophilised peptides reconstituted in bacteriostatic water and stored refrigerated at 2-8 degrees Celsius protected from light.
Are either approved under the Ronin brand for human use?
No. Both Ronin vials are research-grade reagents sold strictly for laboratory and bench-research applications.
References
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998. [PMID 9849822]
- Beck DE et al. A pilot study of ipamorelin on postoperative ileus. Annals of Surgery, 2014. [PMID 24299680]
- Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 2007. [PMID 18046025]
- Falutz J et al. Effects of tesamorelin on visceral fat in HIV. New England Journal of Medicine, 2008. [PMID 18768934]
- Stanley TL et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV. Lancet HIV, 2019. [PMID 31578259]
Comparison pages describe research-context use of the compared compounds. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.